Yet another company hoping to develop a "female Viagra" drug failed in its main objective with BioSante Pharmaceutical confirming that their experimental gel to increase female libido was unable to meet its main objectives in the late-stage efficacy trials.
The company had been hoping that their drug, LibiGel would manage to meet all the requirements in the late stage trials but though it had managed to increase the testosterone levels of the participants, leading to slightly more days with a satisfying sexual event in the trial, it had failed to meet its main goal of increasing their sexual desire.
The news wiped out more than three quarters of BioSante's market value though the company said that it will be reviewing the trial data to chalk out a future strategy for the gel. "We will be looking to see if there are certain subsets of the data whether there is an age of patients who are responding or more likely to respond and so on", the company said.
PPregnancy Weight Gain Raises Baby's Obesity Risk Number of Married Couples in the US Hits Record Low M